MIROGABALIN BESYLATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H19NO2.C6H6O3S
Molecular Weight	367.46
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(=O)(=O)C1=CC=CC=C1.[H][C@@]23C[C@](CN)(CC(O)=O)[C@]2([H])C=C(CC)C3

InChI

InChIKey=OKJXJRVWXYRSAN-TXULWXBWSA-N

InChI=1S/C12H19NO2.C6H6O3S/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8;7-10(8,9)6-4-2-1-3-5-6/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15);1-5H,(H,7,8,9)/t9-,10-,12-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C6H6O3S
Molecular Weight	158.175
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C12H19NO2
Molecular Weight	209.2848
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30672128 | https://www.ncbi.nlm.nih.gov/pubmed/30913164 | https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006800.html

Mirogabalin, a selective alpha 2 delta ligand binds to the α2δ subunits of voltage-dependent calcium channels and thus blocks the channel. This drug was developed by Daiichi Sankyo and in January 2019 was approved in Japan for the treatment of neuropathic pain and for the postherpetic neuralgia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated calcium channel alpha2/delta subunit 1 19 Target ID: CHEMBL1919 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29563324	Binding Agent 1064		13.5 nM [Kd]
Voltage-gated calcium channel alpha2/delta subunit 2 6 Target ID: CHEMBL3896 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29563324	Binding Agent 1064		22.7 nM [Kd]

PubMed

Title	Date	PubMed
The antibiotic, L-beta-(5-hydroxy-2-pyridyl)-alanine specifically inhibits growth of the NIH3T3 cells transformed by activated human c-Ha-ras and induces formation of flat revertant cells.	1988	3067212
Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients.	2019 May	30913164

Patents

Sample Use Guides

In Vivo Use Guide

postherpetic neuralgia: mirogabalin 15, 20, or 30 mg/day for up to 14 weeks peripheral neuropathic pain: mirogabalin 30 mg/day showed statistically significant pain relief

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:17:10 GMT 2023` Edited by `admin` on `Sat Dec 16 09:17:10 GMT 2023`
Record UNII	01F4FRP8YL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MIROGABALIN BESYLATE

Official Name

English

BICYCLO(3.2.0)HEPT-3-ENE-6-ACETIC ACID, 6-(AMINOMETHYL)-3-ETHYL-, (1R,5S,6S)-, BENZENESULFONATE (1:1)

Systematic Name

English

MIROGABALIN BESYLATE [USAN]

Common Name

English

Mirogabalin besilate [WHO-DD]

Common Name

English

[(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate

Systematic Name

English

MIROGABALIN BESILATE [JAN]

Common Name

English

DS5565

Code

English

Mirogabalin besilate

Common Name

English

DS-5565

Code

English

Code System Code Type Description

USAN

CD-60